ArticleAnnals of hematology2025
Non-curative therapies and their impact on the prognosis of patients with myelodysplastic syndromes- a retrospective matched-pairs analysis.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Understanding the evolving role of early palliative care in myelodysplastic syndromes: a 2026 narrative review.Annals of hematology · 2026Review
- Influence of different therapy strategies in patients with myelodysplastic neoplasms (MDS) on overall survival with regard to different decades: data from the German MDS registry.Annals of hematology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allogeneic stem cell transplantation (SCT) remains the only curative therapy for patients with high-risk myelodysplastic syndromes (MDS). Due to age, comorbidities, or lack of urgency, many receive only palliative therapies to improve quality of life. Some patients remain untreated due to a lack of symptoms or low progression risk. Data on the impact of palliative therapies on overall survival (OS) and leukemia-free survival (LFS) are limited. Using the Düsseldorf MDS Registry, we compared outcomes of patients receiving red blood cell transfusions (RBCT) alone to the outcome of patients receiving RBCT combined with iron chelation therapy (ICT), erythropoietin (EPO), antithymoglobulin (ATG), or lenalidomide (LENA). Matched-pairs analysis was conducted using age, gender, and prognostic scores (Revised International Prognostic Scoring System or Chronic Myelomonocytic Leukemia-specific Prognostic Scoring System). ICT-treated patients (n = 85) had significantly improved OS (70 vs. 21 months, p < 0.001) and lower 5-year AML progression (3.5% vs. 28.2%, p < 0.001). Similar benefits were seen with EPO (n = 210; OS: 63 vs. 24 months, p < 0.001; AML: 5.7% vs. 19%, p = 0.007) and LENA (n = 30; OS: 92 vs. 57 months, p = 0.049; AML: 0% vs. 16.7%, p = 0.024). ATG (n = 11) showed no significant improvement in OS (79 vs. 64 months) or AML progression (0% vs. 18.2%). While recognizing the limitations of matched-pairs analysis versus randomized trials, our findings indicate a survival benefit from ICT, EPO, or LENA versus RBCT alone. The year of diagnosis did not independently affect OS or LFS. These results support the use of selected palliative therapies to improve long-term outcomes in MDS patients. KEY POINTS: Treating patients with myelodysplastic syndromes with non-curative therapies beyond red blood cell transfusions like iron chelation therapy, erythropoietin, or lenalidomide has a positive impact on overall survival and leukemia-free survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.